Human Longevity operates a corporate venture capital arm, the Human Longevity and Performance Impact Venture Fund, established in 2020. This fund focuses on early-stage investments in human health technology, predictive analytics, and patient care sectors, primarily within the United States.
100% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-a (100% of deals).
Portfolio
2
Fund Size
—
Top Stage
Series A
Last 12 Mo
0
Portfolio Breakdown
Stage Distribution
Portfolio
2 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Sun Genomics | Series A | $8.7M | Sep 2020 |
| Sun Genomics | Series A | $8.7M | Jun 2020 |
Top Co-Investors
Danone Manifesto Ventures2 shared
SOSV2 shared
Last updated: 28 April 2026